Design of enzyme inhibitors using iterative protein crystallographic analysis.
about
Increasing the structural coverage of tuberculosis drug targetsApplication of crystallographic and modeling methods in the design of purine nucleoside phosphorylase inhibitorsStructure-guided inhibitor design for human FAAH by interspecies active site conversionA phase I study of the lipophilic thymidylate synthase inhibitor Thymitaq (nolatrexed dihydrochloride) given by 10-day oral administrationPreclinical pharmacokinetics and distribution to tissue of AG1343, an inhibitor of human immunodeficiency virus type 1 proteaseProtein structure from x-ray diffraction.Multi-level gene expression profiles affected by thymidylate synthase and 5-fluorouracil in colon cancer.Structure-based drug design approaches for predicting binding affinities of HIV1 protease inhibitors.Macromolecular crystallography as a tool for investigating drug, enzyme and receptor interactions.The statistical-thermodynamic basis for computation of binding affinities: a critical reviewComparative complement selection in bacteria enables screening for lead compounds targeted to a purine salvage enzyme of parasitesHypoxanthine phosphoribosyltransferase from Trypanosoma cruzi as a target for structure-based inhibitor design: crystallization and inhibition studies with purine analogs.The therapeutic potential of targeting the cell cycle.Regulation of p53 expression by thymidylate synthaseResistance to human immunodeficiency virus type 1 protease inhibitors.The chemistry of contact allergy: why is a molecule allergenic?Thymidylate synthase inhibition: a structure-based rationale for drug design.Characterising non-covalent interactions with the Cambridge Structural Database.The evolution of new enzyme function: lessons from xenobiotic metabolizing bacteria versus insecticide-resistant insects.C8-H bond activation vs. C2-H bond activation: from naphthyl amines to lactams.Influence of sugar ring conformation on the transportability of nucleosides by human nucleoside transporters.Molecular mechanics calculations of proteins. Comparison of different energy minimization strategies.Probing the folate-binding site of human thymidylate synthase by site-directed mutagenesis. Generation of mutants that confer resistance to raltitrexed, Thymitaq, and BW1843U89.Is it the shape of the cavity, or the shape of the water in the cavity?Interdisciplinary approaches to drug discovery An academic approach
P2860
Q27644314-7EDC98A3-BDE2-4716-989D-1D1BC6CF0E70Q27646682-8207A676-2786-4746-A205-9AE757FFD6B1Q27651822-4F13633F-9FDA-4B07-9E1C-1E3281458DC7Q30321809-8D5D2080-ED72-46AE-A3DC-DF4E6CF6AAFAQ30425015-27959E22-8C72-40FD-892C-E3971A7100C6Q30426243-7536FF94-2324-4A06-9C38-A150054ECBA4Q33238496-A05E427C-81B5-4E09-AC4A-51A43813D1F2Q33751567-1736C9DB-5FAC-4FA2-9278-EB606AB71D5DQ33879442-6DFDA7BE-3186-4988-A515-DE07D9E5FE02Q33915676-10930B90-4CE4-4B2D-9D5F-FD09B962F331Q35112196-E40EA23E-71F8-4D31-B19F-D2B44ECAB7ABQ35137562-6F1FD735-4DF4-498E-A33E-B74B85B08948Q36181206-DE12447A-3A98-43C3-9114-DE0C459E18A8Q36451021-36A9CAE8-8422-4386-B8B8-AC74F2E9F262Q39559316-C22E5DC2-8BE1-4D99-99ED-EEFF4C40C69DQ40530325-ADD6084B-E866-41CB-BF0E-B572B8DAD25DQ40872442-F78CEAA4-EBB7-47DE-B50A-EC85ECBAF553Q41518687-51C028AF-9FDC-4640-A02E-EDCD1E12A92EQ41837915-1E4953C7-18AB-4E1B-BBEC-E717C86DC661Q48251267-29746E04-9EC1-41BF-98F1-571353C8BE0CQ48662032-E1642ACA-8B7B-4D77-8BD2-F32F8A3BA5DEQ52250653-1CA00B5D-7CB9-466A-9ACE-A3F6685A3BB8Q54117221-67707EDF-CBD1-4E57-875A-2F67A11EDD2DQ58483826-6341E3A3-CA2E-4958-BA44-53D03AB33E51Q58540750-C42F6955-BB52-4937-AEEE-250412B5F59B
P2860
Design of enzyme inhibitors using iterative protein crystallographic analysis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on July 1991
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Design of enzyme inhibitors using iterative protein crystallographic analysis.
@en
Design of enzyme inhibitors using iterative protein crystallographic analysis.
@nl
type
label
Design of enzyme inhibitors using iterative protein crystallographic analysis.
@en
Design of enzyme inhibitors using iterative protein crystallographic analysis.
@nl
prefLabel
Design of enzyme inhibitors using iterative protein crystallographic analysis.
@en
Design of enzyme inhibitors using iterative protein crystallographic analysis.
@nl
P2093
P356
P1476
Design of enzyme inhibitors using iterative protein crystallographic analysis.
@en
P2093
Bacquet RJ
Bartlett CA
Gehring MR
Herrmann SM
Howland EF
P304
P356
10.1021/JM00111A001
P407
P577
1991-07-01T00:00:00Z